Carlsmed is a commercial-stage medical technology company developing AI-enabled solutions for personalized spine surgery. Headquartered in Carlsbad, California, the company is publicly listed on Nasdaq under the ticker symbol CARL, having gone public in 2025.
Its core product is the aprevo® personalized surgery platform, described as the world's only end-to-end system for bespoke spinal devices. The platform uses patient data and proprietary digital technologies - including AI, 3D visualization, and precision alignment - to generate optimized surgical plans and manufacture personalized spine fusion devices. It is FDA-cleared for lumbar and cervical spinal fusion indications and has received the FDA's Breakthrough Device designation.
For engineers, the technical stack spans artificial intelligence, 3D visualization, precision alignment algorithms, and fit optimization - applied directly to a regulated medical hardware and software ecosystem.
